Market Tracking for Anti-VEGF Therapies

Stay Ahead in the Evolving Anti-VEGF Landscape with Verana Health’s Market Insights

The anti-VEGF (vascular endothelial growth factor) market continues to expand with new therapies and competitive dynamics shaping the landscape of ophthalmic care. Verana Health’s Market Tracking solution for anti-VEGF therapies leverages real-world evidence (RWE) derived from real-world data (RWD) from electronic health record (EHR) clinician notes in the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight).

Our solution provides refreshed data and deep insights into the anti-VEGF space, allowing you to stay informed and agile in your decision-making.

Meet with Verana Health

What Is Market Tracking for Anti-VEGF Therapies?

Verana Health’s Market Tracking solution gives you a data-driven view of the ophthalmology market, particularly focusing on the use of anti-VEGF therapies. Our Qdata® Anti-VEGF Market Tracker actively and accurately tracks real-world usage of anti-VEGF therapies in patients with retinal conditions down to the brand level.

Through continuous monitoring of patient treatment patterns and prescriber behaviors, our solution helps life sciences companies make more informed business decisions and maintain their market position.

Meet with Verana Health

Key Features of Verana Health’s Market Tracking Solutions

Monitor shifts in the anti-VEGF market.

Our Market Tracking capabilities offer up-to-date anti-VEGF therapy insights. Leverage Qdata Anti-VEGF Market Tracker to see how treatment patterns and therapy utilization are evolving with details into practice profiles. 

Keep track of the following:

 

  • Anti-VEGF therapy adoption rates
  • Changes in prescriber preferences
  • Trends aligned to your KPIs 
  • Usage by indication, including brand switching

 

Competitive Intelligence

Understand how your anti-VEGF therapy is performing relative to competitors and similar treatments. Track new product launches, market share shifts, and therapy preferences among clinicians. Identify opportunities to differentiate your product based on real-world usage data.

Patient Treatment Pathways

Gain visibility into patient journeys across various anti-VEGF therapies, such as anti-VEGF or complement inhibitors. Monitor market dynamics, track brand initiations, switches, and discontinuations, and analyze treatment frequency.

These valuable insights empower you to better understand treatment patterns and make informed decisions to enhance product positioning in the market.

Exclusive Data and Insights

Society Partnership

Our Market Tracking for anti-VEGF therapies is powered by data from our exclusive partnership with the IRIS Registry, the world’s largest comprehensive eye disease clinical registry, which represents a broad spectrum of ophthalmologists in different geographic regions and subspecialties.

A database with this breadth, depth, and diversity is more representative of the U.S. patient population and ophthalmologist community and helps ensure unparalleled data quality and access to cutting-edge clinical trends.

Comprehensive Data Source

The Qdata Anti-VEGF Market Tracker is curated data from the IRIS Registry to provide a detailed view of the anti-VEGF market across diverse patient populations and clinical settings. This rich RWD offers a comprehensive perspective on real-world usage through an intuitive dashboard.

Meet with the Verana Health Team or View a Demo

Schedule Now

Why Choose Verana Health’s Qdata Anti-VEGF Market Tracker?

Largest Ophthalmology Dataset

Our RWE, derived from RWD within the IRIS Registry, is the most extensive in ophthalmology, providing robust insights into anti-VEGF therapies.

Timely Data

Stay informed with up-to-date market data to ensure that your strategies remain relevant and proactive.

Expert Analytics

Our team combines expertise in data science, ophthalmology, and market analytics to deliver high-quality, actionable insights.

Intuitive Dashboards

Track rolling market share and market dynamics through easy-to-use, self-service dashboards created for day-to-day use.

Featured Content

Research

Impact of Anti-VEGF Treatment and Patient Characteristics on Vision Outcomes in nAMD: Up to 6-Year Analysis of the AAO IRIS® Registry

October 2023
→
Blog

A Powerful and Unique Tool for the Anti-VEGF Market

April 2023
→
Press

Verana Health Unveils Qdata Anti-VEGF Market Tracker

March 2023
→
VeranaHealth_Logo

Unlock Market Insights for Anti-VEGF Therapies Today!